HLAVNÍ TÉMA Current trends in the diagnosis of pancreatic cancer | 369 / Vnitř Lék. 2022;68(6):363-370 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 7. Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 2019; 68:130–9. doi:10.1136/ gutjnl-2017-314828. 8. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. [online]. 2021. [cit. 2021-0829]. Available at: https://seer.cancer.gov/statfacts/html/pancreas.html. 9. Hernandez YG, Lucas AL. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol 2016; 8(1): 18-29. doi: http://dx.doi.org/10.4251/ wjgo.v8.i1.18 10. FalascaM, KimM, Casari I. Pancreatic cancer: Current research and future directions. Biochim Biophys Acta 2016; 1865(2):123-32. doi: 10.1016/j.bbcan.2016.01.001. 11. Gharibi A, Adamian Y, Kelber JA. Cellular andmolecular aspects of pancreatic cancer. Acta Histochem 2016; 118(3):305-16. doi: 10.1016/j.acthis.2016.01.009. 12. Zhang X, Shi S, Zhang B, et al. Circulating biomarkers for early diagnosis of pancreatic ca‑ ncer: facts and hopes. Am J Cancer Res 2018; 8(3):332-353. 13. Ryska M. Karcinom pankreatu – současný efektivní diagnostický a terapeutický postup. Cas Lek Ces 2016; 155:38–43. 14. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Scree‑ ning in High-Risk Individuals: Expert Review. Gastroenterology 2020; 159(1):358-362. doi: 10.1053/j.gastro.2020.03.088. 15. Owens DK, Davidson KW, Krist AH, et al. Screening for pancreatic cancer: US preventi‑ ve services Task force reaffirmation recommendation statement. JAMA 2019; 322:438–44. doi:10.1001/jama.2019.10232. 16. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69(1):7-17. doi: 10.1136/gutjnl-2019-319352. 17. Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2012; 23(7):1880-8. doi: 10.1093/annonc/mdr541. 18. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic ca‑ ncer: a review and meta-analysis. Langenbecks Arch Surg 2008; 393(4):535-45. doi: 10.1007/ s00423-007-0266-2. 19. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet 2020; 395(10242):20082020. doi: 10.1016/S0140-6736(20)30974-0. 20. Stolzenberg-Solomon RZ, Schairer C, Moore S, et al. Lifetime adiposity and risk of pancre‑ atic cancer in the NIH-AARP Diet and Health Study cohort. Am J Clin Nutr 2013; 98(4):1057-65. doi: 10.3945/ajcn.113.058123. 21. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-ana‑ lysis. JAMA 1995;273(20):1605-9. 22. Andersen DK, Korc M, Petersen GM, Eibl G, et al. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes 2017; 66(5):1103-1110. doi: 10.2337/db16-1477. 23. Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adul‑ ts in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 4(3):e137-e147. doi: 10.1016/S2468-2667(18)30267-6. 24. Rebours V, Gaujoux S, d‘Assignies G, et al. Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN). Clin Cancer Res 2015; 21(15):3522-8. doi: 10.1158/1078-0432.CCR-14-2385. 25. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pan‑ creatic cancer kindreds. Cancer Res 2004; 64(7):2634-8. doi: 10.1158/0008-5472.can-03-3823. 26. Schneider R, Slater EP, Sina M, et al. German national case collection for familial pan‑ creatic cancer (FaPaCa): ten years experience. Fam Cancer 2011; 10(2):323-30. doi: 10.1007/ s10689-010-9414-x. 27. Vanek P, Slodicka P, Zoundjiekpon V. Pancreatic cancer screening: ready for prime time?. Gastroent Hepatol 2021; 75(5):390-398. doi: 10.48095/ccgh2021390. 28. Park W, Chawla A, O‘Reilly EM. Pancreatic Cancer: A Review. JAMA 2021; 326(9):851-862. doi: 10.1001/jama.2021.13027. 29. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: a review of clinical diagno‑ sis, epidemiology, treatment and outcomes. World J Gastroenterol 2018; 24(43):4846–4861. doi:10.3748/wjg.v24.i43.4846 30. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71(1):733. doi: 10.3322/caac.21654. 31. Macdonald S, Macleod U, Campbell NC, et al. Systematic reviewof factors influencing pa‑ tient and practitioner delay in diagnosis of upper gastrointestinal cancer. Br J Cancer 2006; 94(9):1272-80. doi: 10.1038/sj.bjc.6603089. 32. Walter FM, Mills K, Mendonça SC, et al. Symptoms and patient factors associatedwith dia‑ gnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. Lancet Gastroenterol Hepatol 2016; 1(4):298-306. doi: 10.1016/S2468-1253(16)30079-6. 33. Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of Pancreatic Cancer in Primary Care: A Systematic Review. Pancreas 2016; 45(6):814-8. doi: 10.1097/MPA.0000000000000527. 34. Kunovsky L, Dite P, Jabandziev P, et al. Causes of Exocrine Pancreatic Insufficiency Other Than Chronic Pancreatitis. J Clin Med 2021; 10(24):5779. doi: 10.3390/jcm10245779. 35. Sharma A, Smyrk TC, Levy MJ, et al. Fasting blood glucose levels provide estimate of du‑ ration and progression of pancreatic cancer before diagnosis. Gastroenterology 2018; 155(2): 490–500. doi: 10.1053/j.gastro.2018.04.025. 36. Sah RP, Sharma A, Nagpal S, et al. Phases of metabolic and soft tissue changes in months preceding a diagnosis of pancreatic ductal adenocarcinoma. Gastroenterology 2019; 156(6): 1742–1752. doi: 10.1053/j.gastro.2019.01.039. 37. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5:v56-68. doi: 10.1093/annonc/mdv295. 38. Lang J, Kunovsky L, Kala Z, Trna J. Risk factors of pancreatic cancer and their possible uses in diagnostics. Neoplasma 2021; 68(2):227-239. doi: 10.4149/neo_2020_200706N699. 39. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis andmanagement of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012; 3(2):105-19. doi: 10.3978/j.issn.2078-6891.2011.021. 40. Kaur S, Baine MJ, Jain M, et al. Early diagnosis of pancreatic cancer: Challenges and new developments. Biomark Med 2012; 6(5): 597–612. doi:10.2217/bmm.12.69. 41. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24(33):5313-27. doi: 10.1200/ JCO.2006.08.2644. 42. Kunovsky L, Tesarikova P, Kala Z, et al. The Use of Biomarkers in Early Diagnostics of Pan‑ creatic Cancer. Can J Gastroenterol Hepatol 2018; 2018:5389820. doi: 10.1155/2018/5389820. 43. Kim JE, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a scree‑ ning test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19(2):182-6. doi: 10.1111/j.1440-1746.2004.03219.x. 44. Eid M, Karousi P, Kunovsky L, et al. The Role of Circulating MicroRNAs in Patients with Ear‑ ly-Stage Pancreatic Adenocarcinoma. Biomedicines 2021; 9(10):1468. doi: 10.3390/biomedi‑ cines9101468. 45. Kau SY, Shyr YM, Su CH, et al. Diagnostic and prognostic values of CA 19-9 and CEA in pe‑ riampullary cancers. J Am Coll Surg 1999; 188(4):415-20. doi: 10.1016/s1072-7515(98)00326-3. 46. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33(3):26670. doi: 10.1016/j.ejso.2006.10.004. 47. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA19-9: clinical interpretati‑ on and influence of obstructive jaundice. Eur J Surg Oncol 2000; 26(5):474-9. doi: 10.1053/ ejso.1999.0925. 48. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol. 2005 Jul 10;23(20):4524-31. doi: 10.1200/JCO.2005.19.711. 49. Fahrmann JF, Schmidt CM, Mao X, et al. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology 2021; 160(4):1373-1383.e6. doi: 10.1053/j.gastro.2020.11.052. 50. Bauer TM, El-Rayes BF, Li X, et al. Carbohydrate antigen 19-9 is a prognostic and predic‑ tive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-con‑ taining chemotherapy: a pooled analysis of 6 prospective trials. Cancer 2013; 119(2):285-92. doi: 10.1002/cncr.27734. 51. Tzeng CW, Balachandran A, AhmadM, et al. Serumcarbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancre‑ atic cancer. HPB (Oxford) 2014; 16(5):430-8. doi: 10.1111/hpb.12154. 52. Wong D, Ko AH, Hwang J, et al. SerumCA19-9 decline compared to radiographic respon‑ se as a surrogate for clinical outcomes in patients withmetastatic pancreatic cancer receiving chemotherapy. Pancreas 2008; 37(3):269-74. doi: 10.1097/MPA.0b013e31816d8185. 53. Pelzer U, Hilbig A, Sinn M, et al. Value of carbohydrate antigen 19-9 in predicting respon‑ se and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Front Oncol 2013; 3:155. doi: 10.3389/fonc.2013.00155. 54. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 2013; 20(7):218896. doi: 10.1245/s10434-012-2809-1. 55. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet 2016; 388(10039):73–85. doi:10.1016/s0140-6736(16)00141-0 56. Zhao Z, LiuW. Pancreatic Cancer: A Reviewof Risk Factors, Diagnosis, and Treatment. Tech‑ nol Cancer Res Treat 2020; 19. doi: 10.1177/1533033820962117. 57. Rawat M, Kadian K, Gupta Y, et al. MicroRNA in Pancreatic Cancer: From Biology to Thera‑ peutic Potential. Genes (Basel) 2019; 10(10):752. doi: 10.3390/genes10100752. 58. Johansen JS, Calatayud D, Albieri V, et al. The potential diagnostic value of serummicroR‑ NA signature in patients with pancreatic cancer. Int J Cancer 2016; 139(10):2312-24. doi: 10.1002/ijc.30291. 59. Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA19-9 for ear‑ ly detection of pancreatic cancer. Int J Cancer 2012; 131(3):683–691. doi:10.1002/ijc.26422 60. Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014; 311(4):392–404, doi:10.1001/jama.2013.284664 61. Shams R, Saberi S, Zali M, et al. Identification of potential microRNA panels for pancre‑ atic cancer diagnosis using microarray datasets and bioinformatics methods. Sci Rep 2020; 10(1):7559. doi: 10.1038/s41598-020-64569-1. 62. Iwagami Y, Eguchi H, Nagano H, et al. miR-320c regulates gemcitabine-resistance in pan‑ creatic cancer via SMARCC1. Br J Cancer 2013; 109(2):502-11. doi: 10.1038/bjc.2013.320. 63. Martini V, Timme-Bronsert S, Fichtner-Feigl S, et al. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers 2019; 11(11). doi:10.3390/cancers11111659.
RkJQdWJsaXNoZXIy NDA4Mjc=